FDA 483 - Zhejiang Jinhua Conba Bio-Pharm. Co., Ltd. - January 22, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Zhejiang Jinhua Conba Bio-Pharm. Co., Ltd., an API manufacturer, revealed significant deficiencies in their quality systems. The firm was cited for incomplete investigations into out-of-specification results and equipment failures, as well as inadequate laboratory controls lacking scientifically sound procedures. Furthermore, the inspection identified insufficient validation of cleaning, manufacturing, and sealing processes, alongside ineffective equipment cleaning and maintenance practices.
ID · 1f800525-7e82-4e4b-bc60-4c96381440f8